However, in a murine preclinical model of prostate cancer, mice who received GVAX prior to anti-CTLA-4 demonstrated increased CD8+ and CD4+ T cells compared to those who received anti-CTLA-4 treatment first [97]. This evidence concerns the gene CD4 and prostate carcinoma.